Patents by Inventor Roland Beckmann

Roland Beckmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING PRURITUS WITH IL-31 MONOCLONAL ANTIBODY FORMULATIONS
    Publication number: 20170313768
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: July 12, 2017
    Publication date: November 2, 2017
    Inventors: Kent Bondensgaard, Roland Beckmann
  • ANTIBODY LIGHT CHAINS
    Publication number: 20170291936
    Abstract: The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 12, 2017
    Inventor: Roland Beckmann
  • REMOVAL OF MONOMERIC TARGETS
    Publication number: 20170253672
    Abstract: The present invention relates to a novel method for the removal of monomeric targets from bodily fluids, and to pharmaceutical compositions for use in such methods.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 7, 2017
    Inventors: Roland Beckmann, Kristian Jensen
  • IL-31 monoclonal antibody formulations
    Patent number: 9738715
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 22, 2017
    Assignees: ZYMOGENETICS INC., MERCK SERONO S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Antibody light chains
    Patent number: 9708388
    Abstract: The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventor: Roland Beckmann
  • IL-31 MONOCLONAL ANTIBODY FORMULATIONS
    Publication number: 20160311898
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: July 13, 2016
    Publication date: October 27, 2016
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Method of treating pruritus with IL-31 monoclonal antibodies
    Patent number: 9416184
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: August 16, 2016
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • DUAL TARGETING
    Publication number: 20150315295
    Abstract: The present invention relates to antibody-based dual targeting molecules, and to methods for generating such dual targeting molecules, including a library-based approach.
    Type: Application
    Filed: December 5, 2013
    Publication date: November 5, 2015
    Inventors: Roland BECKMANN, Kristian JENSEN
  • METHOD OF TREATING PRURITUS WITH IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20150183868
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 2, 2015
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Polynucleotides encoding IL-31 monoclonal antibodies
    Patent number: 9005921
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: April 14, 2015
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • ANTIBODY LIGHT CHAINS
    Publication number: 20150086538
    Abstract: The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 26, 2015
    Inventor: Roland Beckmann
  • Removal of Monomeric Targets
    Publication number: 20140255405
    Abstract: The present invention relates to a novel method for the removal of monomeric targets from bodily fluids, and to pharmaceutical compositions for use in such methods.
    Type: Application
    Filed: May 29, 2012
    Publication date: September 11, 2014
    Inventors: Roland Beckmann, Kristian Jensen
  • ANTIBODIES WITH IMPROVED FOLDING STABILITY
    Publication number: 20140213459
    Abstract: The present invention relates to methods for improving the folding stability of antibodies, to antibodies with improved folding stability, nucleic acid and vectors encoding such antibodies, and to uses of such antibodies, nucleic acid and vectors.
    Type: Application
    Filed: May 29, 2012
    Publication date: July 31, 2014
    Inventor: Roland Beckmann
  • Dual Targeting
    Publication number: 20140206846
    Abstract: The present invention relates to antibody-based dual targeting molecules, and to methods for generating such dual targeting molecules, including a library-based approach.
    Type: Application
    Filed: May 29, 2012
    Publication date: July 24, 2014
    Inventor: Roland Beckmann
  • POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20140186891
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 3, 2014
    Applicants: Merck Serono S/A, ZymoGenetics, Inc.
    Inventors: Kent BONDENSGAARD, Roland Beckmann
  • Nucleic acid molecules encoding humanized antibody molecules specific for IL-31
    Patent number: 8685669
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: April 1, 2014
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • HUMANIZED ANTIBODY MOLECULES SPECIFIC FOR IL-31
    Publication number: 20130295611
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: June 3, 2013
    Publication date: November 7, 2013
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Humanized antibodies against human IL-22RA
    Patent number: 8545844
    Abstract: The invention relates to humanized antibodies against human IL-22RA and to their use in the treatment of psoriasis and other immune-mediated diseases such as psoriatic arthritis and atopic dermatitis.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: October 1, 2013
    Assignee: Merck Serona SA
    Inventors: Roland Beckmann, Caroline Johnson-Leger
  • Humanized antibody molecules specific for IL-31
    Patent number: 8470979
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: June 25, 2013
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • HUMANIZED ANTIBODIES AGAINST HUMAN IL-22RA
    Publication number: 20120230990
    Abstract: The invention relates to humanized antibodies against human IL-22RA and to their use in the treatment of psoriasis and other immune-mediated diseases such as psoriatic arthritis and atopic dermatitis.
    Type: Application
    Filed: November 12, 2010
    Publication date: September 13, 2012
    Applicant: MERCK SERONO SA
    Inventors: Roland Beckmann, Caroline Johnson-Leger